CN100389798C - 荔枝果皮提取物及其制备方法和用途 - Google Patents
荔枝果皮提取物及其制备方法和用途 Download PDFInfo
- Publication number
- CN100389798C CN100389798C CNB2004100225590A CN200410022559A CN100389798C CN 100389798 C CN100389798 C CN 100389798C CN B2004100225590 A CNB2004100225590 A CN B2004100225590A CN 200410022559 A CN200410022559 A CN 200410022559A CN 100389798 C CN100389798 C CN 100389798C
- Authority
- CN
- China
- Prior art keywords
- extract
- fructus litchi
- preparation
- present
- litchi extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 241001629511 Litchi Species 0.000 title claims abstract 6
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000011275 oncology therapy Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 239000002537 cosmetic Substances 0.000 abstract description 11
- 235000013399 edible fruits Nutrition 0.000 abstract description 10
- 238000000605 extraction Methods 0.000 abstract description 10
- 239000002994 raw material Substances 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 244000183278 Nephelium litchi Species 0.000 description 82
- 210000004027 cell Anatomy 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 15
- 206010006187 Breast cancer Diseases 0.000 description 14
- 208000026310 Breast neoplasm Diseases 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 230000003064 anti-oxidating effect Effects 0.000 description 8
- 201000007270 liver cancer Diseases 0.000 description 8
- 208000014018 liver neoplasm Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 201000008275 breast carcinoma Diseases 0.000 description 6
- 235000021022 fresh fruits Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 6
- 229940096397 interleukin-8 Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 4
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101000836222 Homo sapiens Extracellular superoxide dismutase [Cu-Zn] Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 235000015742 Nephelium litchi Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000007765 cera alba Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 2
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 2
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102100027186 Extracellular superoxide dismutase [Cu-Zn] Human genes 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 101000798320 Homo sapiens Bcl-2 homologous antagonist/killer Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 108700025695 Suppressor Genes Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 206010009232 Clang associations Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 102000008142 Cytochrome P-450 CYP1A1 Human genes 0.000 description 1
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101150092794 HO4 gene Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 229920002982 Procyanidin A2 Polymers 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241001093760 Sapindaceae Species 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 108010009442 cytochrome b245 Proteins 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000000495 immunoinflammatory effect Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004137 mechanical activation Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- NSEWTSAADLNHNH-UHFFFAOYSA-N pavetannin A-2 Natural products OC1CC2=C(O)C=C3OC(C4O)(C=5C=C(O)C(O)=CC=5)OC5=CC(O)=CC(O)=C5C4C3=C2OC1C1=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000006659 positive regulation of apoptotic process Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- NSEWTSAADLNHNH-LSBOWGMISA-N proanthocyanidin A2 Chemical compound C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-LSBOWGMISA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100225590A CN100389798C (zh) | 2004-05-19 | 2004-05-19 | 荔枝果皮提取物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100225590A CN100389798C (zh) | 2004-05-19 | 2004-05-19 | 荔枝果皮提取物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1698676A CN1698676A (zh) | 2005-11-23 |
CN100389798C true CN100389798C (zh) | 2008-05-28 |
Family
ID=35475027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100225590A Expired - Fee Related CN100389798C (zh) | 2004-05-19 | 2004-05-19 | 荔枝果皮提取物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100389798C (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101463028B (zh) * | 2007-12-18 | 2012-04-11 | 广东省农业科学院蚕业与农产品加工研究所 | 一种荔枝花青素的生产技术 |
CN101491319B (zh) * | 2008-12-17 | 2011-09-07 | 叶贤忠 | 一种用柑、桔皮制造陈皮及防垢防腐除垢剂的方法 |
CN102028165A (zh) * | 2010-12-15 | 2011-04-27 | 吴剑生 | 荔枝核加工方法 |
CN102093175B (zh) * | 2011-02-15 | 2013-07-31 | 华南农业大学 | 一种从无患子科植物荔枝、龙眼提取白坚木皮醇的方法 |
CN102329535B (zh) * | 2011-08-01 | 2013-12-18 | 中山市丽莎涂料有限公司 | 一种柑橘类植物果皮提取物及其提取方法 |
CN103271304A (zh) * | 2013-04-09 | 2013-09-04 | 广东药学院 | 一种提高荔枝皮提取物稳定性的组合物及提高荔枝皮提取物稳定性的方法 |
CN107494737B (zh) * | 2017-10-13 | 2020-12-08 | 深圳职业技术学院 | 一种荔枝酸奶的生产方法 |
CN108294313A (zh) * | 2018-04-06 | 2018-07-20 | 张奉明 | 一种美容保健的铁皮石斛组合物及其制备方法 |
CN114344211A (zh) * | 2021-12-28 | 2022-04-15 | 广州戊戌科技有限公司 | 一种保湿维稳组合物及其制备方法 |
-
2004
- 2004-05-19 CN CNB2004100225590A patent/CN100389798C/zh not_active Expired - Fee Related
Non-Patent Citations (10)
Title |
---|
荔枝果皮多酚氧化酶酶促褐变的研究. 谭兴杰等.植物生理学报,第13卷第2期. 1987 |
荔枝果皮多酚氧化酶酶促褐变的研究. 谭兴杰等.植物生理学报,第13卷第2期. 1987 * |
荔枝果皮抗氧化作用研究. 郑公铭等.天然产物研究与开发,第15卷第4期. 2003 |
荔枝果皮抗氧化作用研究. 郑公铭等.天然产物研究与开发,第15卷第4期. 2003 * |
荔枝果皮抗氧化物的提取效果及工艺条件研究. 郑公铭等.中国油脂,第28卷第5期. 2003 |
荔枝果皮抗氧化物的提取效果及工艺条件研究. 郑公铭等.中国油脂,第28卷第5期. 2003 * |
荔枝果皮精油的超临界萃取研究及精油成分分析. 江梅等.热带作物学报,第21卷第2期. 2000 |
荔枝果皮精油的超临界萃取研究及精油成分分析. 江梅等.热带作物学报,第21卷第2期. 2000 * |
荔枝皮抗氧化性研究. 郑公铭.精细化工,第19卷第8期. 2002 |
荔枝皮抗氧化性研究. 郑公铭.精细化工,第19卷第8期. 2002 * |
Also Published As
Publication number | Publication date |
---|---|
CN1698676A (zh) | 2005-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5667358B2 (ja) | 柑橘類果皮の麹菌発酵組成物 | |
CN1271083C (zh) | 从竹子中提取的三萜总皂甙元的组成、方法及其用途 | |
CN100389798C (zh) | 荔枝果皮提取物及其制备方法和用途 | |
CN101890030B (zh) | 抗菌、抗病毒、抗氧化及抗色素沉积的组合物 | |
CN1255138C (zh) | 一种对酒精性肝损伤具有辅助保护作用的中药制剂及制备方法 | |
CN102686227B (zh) | 一种使用麦麸提取物或由其分离得到的活性成分治疗肥胖症的组合物 | |
CN101780242B (zh) | 一种保健或药品组合物及其制备方法和用途 | |
CN106421208B (zh) | 一种具有抗化学性肝损伤功能的药物组合物及其制备方法 | |
CN109937795B (zh) | 一种以茉莉花为基质培育虫草菌丝体的方法 | |
CN101948453B (zh) | Neo-克罗烷型二萜化合物及其应用 | |
CN1218745C (zh) | 一种保肝护肝及调节血脂的保健食品及其制备方法 | |
CN101077873B (zh) | 新的neo-克罗烷型二萜化合物及其应用 | |
CN101711790A (zh) | 一种用于治疗肝癌的野生核桃楸树皮水提取物 | |
CN106038799A (zh) | 治疗宫颈癌的药物组合物及其制备方法 | |
CN102293959B (zh) | 一种抗癌中药及其制备方法 | |
CN102805829B (zh) | 土茯苓提取物的制备方法及其在肿瘤治疗中的应用 | |
CN101057876A (zh) | 糙叶败酱苷元提取物及其制备方法和抗结肠癌用途 | |
CN110325195A (zh) | 脂肪细胞分化抑制剂、用于抑制脂肪细胞分化的食品组合物及脂肪细胞分化抑制剂的制造方法 | |
CN101574384A (zh) | 以人参须为原料制备抗癌药物制剂与保健食品的生产方法 | |
CN106310116A (zh) | 一种莪术油及其用途和药物制剂 | |
CN111544440A (zh) | 地奥司明及组合物在制备抗肥胖的产品方面中的应用 | |
CN108324751A (zh) | 一种野葛叶醇提物以及其在解酒护肝中的用途 | |
CN108635445A (zh) | 岩陀黄酮、黄柏黄酮和当归多糖复合物在制备兽药中的应用 | |
CN102188459A (zh) | 一种鸦胆子总萜提取物及其制备方法和用途 | |
Gupta et al. | Herbal Plant Extracts of Gentianakurroo and Rauwolfia serpentine Its Implications In-Breast Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: CHENGDU HUAXI HAIQI MEDICAL TECHNOLOGY Co.,Ltd. Assignor: WEST CHINA HOSPITAL OF SICHUAN University Contract fulfillment period: 2009.11.1 to 2015.5.1 Contract record no.: 2009510000155 Denomination of invention: Litchi peel extract, its preparation method and purposes Granted publication date: 20080528 License type: Exclusive license Record date: 20091113 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.11.1 TO 2015.5.1; CHANGE OF CONTRACT Name of requester: CHENGDU HUAXI HAIQI MEDINE TECHNOLOGY CO., LTD. Effective date: 20091113 |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080528 Termination date: 20130519 |